IASP, NeuPSIG Urge Addition of Gabapentin to WHO List of Essential Medicines
Jan 31, 2017
The WHO Expert Committee on the Selection and Use of Essential Medicines will meet in Geneva, Switzerland, March 27-31, to revise and update the WHO Model List of Essential Medicines (EML). IASP, in conjunction with NeuPSIG and the International Association of Hospice and Palliative Care, have asked the committee to include gabapentin in the EML for the management of neuropathic pain.
Thirty IASP chapters have endorsed the application. In conveying the endorsements to the WHO committee, IASP President Judith A. Turner noted that amitriptyline currently is the only medicine that the EML recommends as a first or second-line treatment in the management of neuropathic pain. “Unfortunately,” she wrote, “limiting treatment to amitriptyline reduces medical options when initial treatment fails or contraindications arise.”
The WHO Expert Committee is soliciting comments via email until February 24 regarding potential changes to the EML. IASP urges interested members to comment on the application and advocate for inclusion of gabapentin on the list.